The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.

Replimune Group ( REPL, Financials) shares surged 17% to $11.85 as of 10:18 a.m. ET Tuesday after the U.S. Food and Drug Administration granted Priority Review for its Biologics License Application ...

The confirmatory IGNYTE-3 trial is assessing RP1 in combination with nivolumab in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for ...

The possibility that Alzheimer’s disease diagnosis is associated with viruses, bacteria, fungi, and parasites has been ...

The World Health Organization (WHO) recently released new estimates suggesting around 846 million people aged between 15 and ...

A cold sore normally clears up on its own within two weeks - but if you need a helping hand, we've asked doctors how to get ...

A new study has uncovered a surprising link between Alzheimer’s disease and Herpes Simplex Virus-1 (HSV-1). Researchers found ...

Some types of meningitis are contagious. You can get it from respiratory droplets in close contact with someone. Learn about ...

Lab-grown mini-brains help scientists explore how concussions reactivate latent viral infections, triggering molecular ...

The global dehydrated culture media market is experiencing significant growth, with projections estimating a market value of ...